Press-release for stocks in the manufacturing sector for immunitybio inc

Prices are updated after-hours

sector : Manufacturing entities : Immunitybio inc

save search

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Published: 2024-04-23 (Crawled : 07:00) - biospace.com/
IBRX | $4.815 -12.3% -14.02% 7.9M

Manufacturing

| -8.63% | O: 16.59% H: 0.65% C: -10.73%
il-15 anktiva fda agonist approval bladder cancer for

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
Published: 2024-03-06 (Crawled : 14:30) - immunitybio.com
IBRX | $4.815 -12.3% -14.02% 7.9M

Manufacturing

| 0.0% | O: 4.15% H: 2.59% C: 1.2%
control hiv therapy study

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
Published: 2024-03-05 (Crawled : 14:30) - immunitybio.com
IBRX | $4.815 -12.3% -14.02% 7.9M

Manufacturing

| -4.93% | O: -1.38% H: 6.6% C: -3.6%
cure natural positive hiv potential study

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
Published: 2024-02-21 (Crawled : 15:00) - biospace.com/
IBRX | $4.815 -12.3% -14.02% 7.9M

Manufacturing

| 1.9% | O: 1.27% H: 0.31% C: -2.3%
first vaccine cancer trial

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
Published: 2024-02-05 (Crawled : 14:30) - immunitybio.com
IBRX | $4.815 -12.3% -14.02% 7.9M

Manufacturing

| 16.43% | O: -1.93% H: 1.35% C: -0.49%
favorable bladder cancer trial plus study

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
Published: 2024-01-02 (Crawled : 12:00) - nantkwest.com
IBRX | $4.815 -12.3% -14.02% 7.9M

Manufacturing

| -3.98% | O: -0.6% H: 5.01% C: 5.01%
million total

ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
Published: 2023-11-16 (Crawled : 14:30) - nantkwest.com
IBRX | $4.815 -12.3% -14.02% 7.9M

Manufacturing

| 17.85% | O: 0.98% H: 2.42% C: -0.97%
conference

First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity
Published: 2023-11-07 (Crawled : 15:00) - nantkwest.com
IBRX | $4.815 -12.3% -14.02% 7.9M

Manufacturing

| 33.89% | O: -0.83% H: 3.92% C: 1.68%
lung cancer cell meeting show

FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
Published: 2023-10-26 (Crawled : 14:00) - nantkwest.com
IBRX | $4.815 -12.3% -14.02% 7.9M

Manufacturing

| 205.06% | O: 6.96% H: 23.67% C: 21.3%
fda resubmission pdufa

ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ
Published: 2023-10-23 (Crawled : 13:30) - biospace.com/
IBRX | $4.815 -12.3% -14.02% 7.9M

Manufacturing

| 270.77% | O: 7.69% H: 14.29% C: 2.14%
resubmission license bladder cancer application

ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities
Published: 2023-09-11 (Crawled : 11:00) - biospace.com/
IBRX | $4.815 -12.3% -14.02% 7.9M

Manufacturing

| 273.64% | O: 0.78% H: 19.23% C: 18.46%

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit
Published: 2023-08-14 (Crawled : 17:00) - prnewswire.com
IBRX | $4.815 -12.3% -14.02% 7.9M

Manufacturing

| 163.39% | O: -0.55% H: 3.85% C: 1.65%
SE | $63.27 2.03% -0.38% 6.3M

Technology Services

| 9.44% | O: -2.2% H: 0.96% C: 0.64%
NVCR | $12.35 2.45% 2.39% 1.1M

Health Technology

| -60.5% | O: -0.93% H: 0.19% C: 0.03%

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit
Published: 2023-08-04 (Crawled : 14:00) - prnewswire.com
IBRX | $4.815 -12.3% -14.02% 7.9M

Manufacturing

| 127.9% | O: 1.89% H: 0.0% C: 0.0%
TIGR | $3.35 -0.89% -0.9% 810K

Finance

| -20.43% | O: -0.71% H: 0.48% C: -1.67%

ImmunityBio Names Enrique Diloné as Chief Technology Officer
Published: 2023-08-03 (Crawled : 13:20) - nantkwest.com
IBRX | $4.815 -12.3% -14.02% 7.9M

Manufacturing

| 148.45% | O: 1.03% H: 11.73% C: 7.91%
technology